Skip to content
Search

Latest Stories

Britain to probe Ultra Electronics takeover to assess national security risks

Britain to probe Ultra Electronics takeover to assess national security risks

BRITAIN has decided to probe the US takeover of defence group to assess risks to national security.

The recent takeover of UK defence technology firm Ultra Electronics by US-owned Cobham has come under scrutiny now.


Business Secretary Kwasi Kwarteng revealed late Wednesday (18) that he has referred the deal to the Competition and Markets Authority (CMA) regulator, which will report back in January next year.

"I instructed the CMA to investigate the proposed acquisition of Ultra Electronics by Cobham to assess any national security concerns," Kwarteng tweeted.

"The UK is open for business, however, foreign investment must not threaten our national security."

Ultra Electronics this week accepted a £2.6 billion ($3.6bn) takeover from Cobham, the former London-listed defence giant now owned by Advent.

Cobham launched the Ultra bid late last month, but the transaction is sensitive because the group has lucrative UK military contracts, including with the Royal Navy for sonar systems.

Kwarteng has also tabled an order in parliament to stop Ultra Electronics from disclosing sensitive information to Cobham about the goods or services it provides to the UK government or its armed forces.

US private equity group Advent bought Cobham in a £4.0bn deal approved by the UK government after a national security probe.

Advent has pledged to protect sensitive government information and keep Cobham's headquarters in Britain.

Cobham is known for pioneering technology enabling the mid-air refuelling of planes, while it also makes electronic warfare systems and communications for military vehicles.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less